Long-term toxicity of cisplatin in germ-cell tumor survivors

M. Chovanec, M. Abu Zaid, Nasser Hanna, N. El-Kouri, Lawrence Einhorn, Costantine Albany

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Context: Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach, including cisplatin-based chemotherapy has resulted in cure in the majority of patients with GCT. Thus, the life expectancy of survivors will extend to many decades post-diagnosis. Late treatment toxicities associated with cisplatin-based chemotherapy may impact their future health. Objective: To systematically evaluate evidence regarding the long-term toxicity of cisplatin in GCT survivors. Evidence acquisition: We carried out a critical review of PubMed/Medline in February 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) criteria. Eighty-three publications were selected for inclusion in this analysis. Evidence synthesis: Included reports evaluated long-term toxicities of cisplatin-based chemotherapy in GCT survivors. Studies reporting neuro- and ototoxicity, secondary malignancies, cardiovascular, renal and pulmonary toxicities, hypogonadism and infertility were found. Seven studies (8%) reported genetic underpinnings of long-term toxicities and 3 (4%) and 14 (19%) studies correlated long-term toxicities with circulating platinum levels and cumulative dose of cisplatin, respectively. Significant risks for long-term toxicities associated with cisplatin and platinum-based regimens were reported. The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals. Conclusions: GCT survivors cured with cisplatin-based chemotherapy are at risk for long-term side-effects. Detection of singlenucleotide polymorphisms could be a valuable tool for predicting long-term toxicities. Patient summary: Herein, this article summarizes the available evidence of long-term toxicity of cisplatin-based chemotherapy in GCT survivors and provide insights from Indiana University.

Original languageEnglish (US)
Pages (from-to)2670-2679
Number of pages10
JournalAnnals of Oncology
Volume28
Issue number11
DOIs
StatePublished - Jan 1 2017

Fingerprint

Germ Cell and Embryonal Neoplasms
Cisplatin
Survivors
Drug Therapy
Platinum
Hypogonadism
Life Expectancy
PubMed
Infertility
Single Nucleotide Polymorphism
Publications
Meta-Analysis
Kidney
Lung

Keywords

  • Cisplatin
  • Germ-cell tumor
  • Late toxicity
  • Quality of life
  • Survivor
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Long-term toxicity of cisplatin in germ-cell tumor survivors. / Chovanec, M.; Abu Zaid, M.; Hanna, Nasser; El-Kouri, N.; Einhorn, Lawrence; Albany, Costantine.

In: Annals of Oncology, Vol. 28, No. 11, 01.01.2017, p. 2670-2679.

Research output: Contribution to journalReview article

Chovanec, M, Abu Zaid, M, Hanna, N, El-Kouri, N, Einhorn, L & Albany, C 2017, 'Long-term toxicity of cisplatin in germ-cell tumor survivors', Annals of Oncology, vol. 28, no. 11, pp. 2670-2679. https://doi.org/10.1093/annonc/mdx360
Chovanec, M. ; Abu Zaid, M. ; Hanna, Nasser ; El-Kouri, N. ; Einhorn, Lawrence ; Albany, Costantine. / Long-term toxicity of cisplatin in germ-cell tumor survivors. In: Annals of Oncology. 2017 ; Vol. 28, No. 11. pp. 2670-2679.
@article{29f34597f79f4048ae185cfc9341a071,
title = "Long-term toxicity of cisplatin in germ-cell tumor survivors",
abstract = "Context: Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach, including cisplatin-based chemotherapy has resulted in cure in the majority of patients with GCT. Thus, the life expectancy of survivors will extend to many decades post-diagnosis. Late treatment toxicities associated with cisplatin-based chemotherapy may impact their future health. Objective: To systematically evaluate evidence regarding the long-term toxicity of cisplatin in GCT survivors. Evidence acquisition: We carried out a critical review of PubMed/Medline in February 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) criteria. Eighty-three publications were selected for inclusion in this analysis. Evidence synthesis: Included reports evaluated long-term toxicities of cisplatin-based chemotherapy in GCT survivors. Studies reporting neuro- and ototoxicity, secondary malignancies, cardiovascular, renal and pulmonary toxicities, hypogonadism and infertility were found. Seven studies (8{\%}) reported genetic underpinnings of long-term toxicities and 3 (4{\%}) and 14 (19{\%}) studies correlated long-term toxicities with circulating platinum levels and cumulative dose of cisplatin, respectively. Significant risks for long-term toxicities associated with cisplatin and platinum-based regimens were reported. The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals. Conclusions: GCT survivors cured with cisplatin-based chemotherapy are at risk for long-term side-effects. Detection of singlenucleotide polymorphisms could be a valuable tool for predicting long-term toxicities. Patient summary: Herein, this article summarizes the available evidence of long-term toxicity of cisplatin-based chemotherapy in GCT survivors and provide insights from Indiana University.",
keywords = "Cisplatin, Germ-cell tumor, Late toxicity, Quality of life, Survivor, Treatment",
author = "M. Chovanec and {Abu Zaid}, M. and Nasser Hanna and N. El-Kouri and Lawrence Einhorn and Costantine Albany",
year = "2017",
month = "1",
day = "1",
doi = "10.1093/annonc/mdx360",
language = "English (US)",
volume = "28",
pages = "2670--2679",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Long-term toxicity of cisplatin in germ-cell tumor survivors

AU - Chovanec, M.

AU - Abu Zaid, M.

AU - Hanna, Nasser

AU - El-Kouri, N.

AU - Einhorn, Lawrence

AU - Albany, Costantine

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Context: Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach, including cisplatin-based chemotherapy has resulted in cure in the majority of patients with GCT. Thus, the life expectancy of survivors will extend to many decades post-diagnosis. Late treatment toxicities associated with cisplatin-based chemotherapy may impact their future health. Objective: To systematically evaluate evidence regarding the long-term toxicity of cisplatin in GCT survivors. Evidence acquisition: We carried out a critical review of PubMed/Medline in February 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) criteria. Eighty-three publications were selected for inclusion in this analysis. Evidence synthesis: Included reports evaluated long-term toxicities of cisplatin-based chemotherapy in GCT survivors. Studies reporting neuro- and ototoxicity, secondary malignancies, cardiovascular, renal and pulmonary toxicities, hypogonadism and infertility were found. Seven studies (8%) reported genetic underpinnings of long-term toxicities and 3 (4%) and 14 (19%) studies correlated long-term toxicities with circulating platinum levels and cumulative dose of cisplatin, respectively. Significant risks for long-term toxicities associated with cisplatin and platinum-based regimens were reported. The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals. Conclusions: GCT survivors cured with cisplatin-based chemotherapy are at risk for long-term side-effects. Detection of singlenucleotide polymorphisms could be a valuable tool for predicting long-term toxicities. Patient summary: Herein, this article summarizes the available evidence of long-term toxicity of cisplatin-based chemotherapy in GCT survivors and provide insights from Indiana University.

AB - Context: Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach, including cisplatin-based chemotherapy has resulted in cure in the majority of patients with GCT. Thus, the life expectancy of survivors will extend to many decades post-diagnosis. Late treatment toxicities associated with cisplatin-based chemotherapy may impact their future health. Objective: To systematically evaluate evidence regarding the long-term toxicity of cisplatin in GCT survivors. Evidence acquisition: We carried out a critical review of PubMed/Medline in February 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) criteria. Eighty-three publications were selected for inclusion in this analysis. Evidence synthesis: Included reports evaluated long-term toxicities of cisplatin-based chemotherapy in GCT survivors. Studies reporting neuro- and ototoxicity, secondary malignancies, cardiovascular, renal and pulmonary toxicities, hypogonadism and infertility were found. Seven studies (8%) reported genetic underpinnings of long-term toxicities and 3 (4%) and 14 (19%) studies correlated long-term toxicities with circulating platinum levels and cumulative dose of cisplatin, respectively. Significant risks for long-term toxicities associated with cisplatin and platinum-based regimens were reported. The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals. Conclusions: GCT survivors cured with cisplatin-based chemotherapy are at risk for long-term side-effects. Detection of singlenucleotide polymorphisms could be a valuable tool for predicting long-term toxicities. Patient summary: Herein, this article summarizes the available evidence of long-term toxicity of cisplatin-based chemotherapy in GCT survivors and provide insights from Indiana University.

KW - Cisplatin

KW - Germ-cell tumor

KW - Late toxicity

KW - Quality of life

KW - Survivor

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85034093274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034093274&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx360

DO - 10.1093/annonc/mdx360

M3 - Review article

VL - 28

SP - 2670

EP - 2679

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -